MedTrace Logo

Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease

NCT02212678 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2019-05-16

Study results available
· View outcomes & findings →

Summary

The investigators are interested in evaluating the use of oral N-acetylcysteine (NAC) as therapy for Parkinson's Disease (PD) and measuring changes in brain and blood chemistry.

Conditions

  • Parkinson Disease

Interventions

DRUG

N-acetylcysteine capsule

N-acetylcysteine capsule

Sponsors & Collaborators

Principal Investigators

  • Paul Tuite, MD · University of Minnesota

  • Lisa Coles, PhD · University of Minnesota

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02212678 on ClinicalTrials.gov